VIVEbiotech
San Sebastián, Spain
Program data pending ClinicalTrials.gov matching
—
Not Assessed
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesLentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press9 articles
Manufacturing site information being gathered
Modalities: Lentiviral
Capacity assessment: 50.0/100
Recent News 9 articles
Lowering Cell and Gene Therapy Production Costs - Genetic Engineering and Biotechnology News
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities - PR Newswire
VIVEbiotech Secures Investment to Expand Lentiviral Vector Manufacturing - Contract Pharma
VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck - PharmiWeb.com
VIVEbiotech’s Lentiviral Vector Manufacturing Plant, San Sebastian - Pharmaceutical Technology
Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck - Fierce Pharma
VIVEbiotech - The Pharma Letter
With demand surging for lentiviral vectors, CDMO VIVEbiotech expands capacity 400% in cross-town move - Fierce Pharma
The rising demand for lentiviral vectors for in vivo gene therapy - Drug Target Review
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: